FY2024 EPS Estimates for Pharma-Bio Serv, Inc. (OTCMKTS:PBSV) Cut by Analyst

Pharma-Bio Serv, Inc. (OTCMKTS:PBSV) – Investment analysts at Zacks Small Cap decreased their FY2024 EPS estimates for Pharma-Bio Serv in a research note issued to investors on Tuesday, September 17th. Zacks Small Cap analyst B. Sorensen now anticipates that the company will earn $0.00 per share for the year, down from their prior estimate of $0.04. The consensus estimate for Pharma-Bio Serv’s current full-year earnings is $0.04 per share.

Pharma-Bio Serv (OTCMKTS:PBSV) last issued its quarterly earnings data on Monday, September 16th. The company reported ($0.01) earnings per share for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.04). The firm had revenue of $2.42 million during the quarter, compared to analyst estimates of $3.50 million. Pharma-Bio Serv had a negative return on equity of 0.04% and a negative net margin of 0.05%.

Pharma-Bio Serv Price Performance

PBSV stock opened at $0.64 on Wednesday. The firm has a 50-day simple moving average of $0.62 and a 200-day simple moving average of $0.69. Pharma-Bio Serv has a 52 week low of $0.52 and a 52 week high of $1.09.

About Pharma-Bio Serv

Pharma-Bio Serv, Inc operates as a compliance and technology transfer services consulting firm in Puerto Rico, the United States, Europe, Brazil, and internationally. The company provides technical compliance consulting services comprising regulatory compliance, validation, technology transfer, engineering, project management, and process support for the pharmaceutical, chemical manufacturing, biotechnology, medical device, cosmetic, food industries, and allied products companies.